Fujifilm to acquire digital pathology company Inspirata; 2nd image deal in a week

Preview

来源: FierceBiotech

Fujifilm continued its push into healthcare digital imaging with the proposed acquisition of Inspirata, marking a second investment for a an imaging company by the Japanese conglomerate in a week.

Fujifilm is set to acquire digital pathology partner Inspirata, marking a second investment for a healthcare imaging company by the large Japanese conglomerate in a week.

With the deal, Fujifilm gets access to Florida-based Inspirata’s Dynamyx digital pathology technology. The technology will help Fujifilm expand its Synapse Enterprise Imaging line to offer integration of pathology images and data into a healthcare organization’s electronic health record system as part of helping to streamline care delivery for oncology patients and provider teams, the company said in a Dec. 19 press release.

Financial terms of the deal, which is expected to close early next year, weren’t disclosed.

Future releases of Dynamyx are expected to support pharmaceutical and contract research organizations with toxicity testing data management for drug development, the company said.

“Acquiring Inspirata’s digital pathology business allows Fujifilm to be an even stronger healthcare partner—bridging a technological gap between pathology, radiology and oncology to facilitate a more collaborative approach to care delivery across the enterprise,” Teiichi Goto, Fujifilm’s president, CEO and representative director, said in the release.

News of the Inspirata sale comes a week after Fujifilm announced it was investing an undisclosed amount in San Diego-based PhenoVista Biosciences to gain access to its imaging-based assay services. PhenoVista is a CRO that provides customized, imaging-based phenotypic assay services for customers from local startups to multinational organizations.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。